You are here: Industry Insights > GSK

News List

GSK sells rare disease drugs, including groundbreaking Strimvelis pharmaphorum
April 13, 2018
GlaxoSmithKline’s (GSK) CEO Emma Walmsley has been in the hot seat for more than a year and is beginning to make some big calls
GSK Divests Rare Disease Gene Therapy Business to Orchard Therapeutics biospace
April 13, 2018
GlaxoSmithKline Chief Executive Officer Emma Walmsley continues to trim excess fat from the company.
GSK to buyout consumer healthcare business from Novartis for $13bn pharmaceutical-technology
April 09, 2018
GlaxoSmithKline has agreed to buy Novartis’ 36.5% stake in the companies’ consumer healthcare joint venture for $13bn.
Teva spared payout to GSK over patent infringement dispute pharmafile
March 30, 2018
Teva has been spared a sizeable payout to GlaxoSmithKline after a federal judge overturned a US jury verdict demanding that the Israeli firm hand over $235 million in damages related to infringement of one of the latter’s patents.
GSK to pay $13bn for Novartis stake in OTC joint venture pharmaphorum
March 28, 2018
GlaxoSmithKline is to buy out Novartis from their over-the-counter joint venture, and may sell its Horlicks business to fund the £9.2 billion ($13bn) acquisition.
GSK passes up Pfizer consumer buy, shares rise pharmaphorum
March 27, 2018
GlaxoSmithKline’s chief executive Emma Walmsley has just taken one of her most challenging decisions to date– and it look like investors are backing her.
GSK trials Benlysta/rituximab combo for lupus pharmatimes
March 23, 2018
GlaxoSmithKline has kicked off a Phase III trial assessing its lupus drug Benlysta in combination with rituximab in adult patients with the condition.
GSK welcomes Brexit transition deal, but wants more ‘precision’ on final relationship pharmaphorum
March 21, 2018
The chief executive of GlaxoSmithKline has welcomed the breakthrough in talks between the UK and EU27 countries on a transition or ‘implementation’ period.
GSK expects Brexit admin to cost £70m pharmaphorum
March 19, 2018
GlaxoSmithKline expects Brexit to cost it £70m over the next three years, with ongoing costs of £50m, according to estimates in its annual report.
GSK loses £37m appeal over pay-to-delay tactics to block Seroxat competition pharmafile
March 12, 2018
GSK has suffered a sizeable blow after losing an appeal disputing that it had engaged in anti-competitive pay-to-delay tactics to block generic versions of its blockbuster antidepressant Seroxat from reaching the market.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 40 41 Next page